Background: In low incomes country, management and follow up of prostate cancer were hard due to difficult to earn drug and difficult access of new test imaging. We explore the epidemiological and diagnostic aspects of prostate cancer at regional university hospital of Parakou from 1st January 2017 to 1st January 2019. Objective: To study diagnostic and clinical aspects of prostate cancer at regional university hospital of Parakou. Methodology: This study was descriptive with prospective data collection (1st January 2017 to 1st January 2019). Patients who were admitted to the department were included. Demographic, clinical and anatomopathological variables were studied. Result: Eighty-one patients were included; the hospital prevalence is 1.6%. The mean year old of patients was sixty-nine years old ± 10 years old (farthest 45 years old and 95 years old). More than half patients were seventy years old. The medical past history of family cancer were found in 6.1% of cases. The complaints were voiding difficult in 54.3% of cases, urinary frequency in 46.9% of cases, complete urine retention in 28.4% of cases and bones pain in 14.8% of cases. The average time of consultation was 24.3 months (farthest 2 months and 48 months). The mean of prostate specific antigen (PSA) was 93.1 ng/ml (farthest 4 ng/ml and 1000 ng/ml). Adenocarcinoma was found in 84.1% of cases. Classic X-ray imaging was used in most cases to detect metastasis. Five patients had done thoracic-abdominal-pelvis tomography. Sixty-six patients (81.5% of cases) were prostate cancer metastasis. Conclusion: Prostate cancer was frequently disease in seventy years old patients. Diagnostic was late in this study. Awareness campaign of patients for early consult was recommended.
References
[1]
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., et al. (2002) The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourology and Urodynamics: Official Journal of the International Continence Society, 21, 167-178. https://doi.org/10.1002/nau.10052
[2]
Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254
[3]
Richard, F. (1994) Epidemiological of Prostate Cancer and Its Public Health Implications: Prostate Cancer. La Revue du Praticien, 44, 575-579.
[4]
Ouattara, A., Hodonou, R., Avakoudjo, J., Cisse, D., Zango, B., Gandaho, I., et al. (2012) Epidemiological of Urologic Cancers at University Hospital Hubert Koutoukou Maga Cotonou, Republic of Benin. Hospital Series Analysis of One-Hundred-Fifty-Eight Cases. Progrès en Urologie, 22, 261-265. https://doi.org/10.1016/j.purol.2011.12.003
[5]
Villers, A. and Chautard, D. (2000) Free PSA: Frequently Use Is Premature for Prostate Cancer Screen. Progrès en Urologie, 10, 618-621.
[6]
Zango, B., Ambou, T.K., Ompo, O.L., Sanon, A.J., Traore, A.C., Bonkoungou, B., et al. (2001) Management of Prostate Cancer at National Hospital of Bobo-Dioulasso Sanou Souro: About One-Hundred-Twenty-One Cases. Science et Technique, Sciences de la santé, 24, 79-87.
[7]
Diallo, A.B., Bah, I., Barry, A.M., Dombeu, N.Y., Barry, M. and Diallo, M.B. (2008) Epidemiological Profile of Prostate Cancer in Guinea. African Journal of Urology, 14, 161-167.
[8]
Yaturu, S., Djedjos, S., Alferos, G. and Deprisco, C. (2006) Bone Mineral Density Changes on Androgen Deprivation Therapy for Prostate Cancer and Response to Antiresorptive Therapy. Prostate Cancer and Prostatic Diseases, 9, 35. https://doi.org/10.1038/sj.pcan.4500846
[9]
Rozet, F., Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., et al. (2015) Management of Prostate Cancer of Low Risk. Progrès en Urologie, 25, 1-10. https://doi.org/10.1016/j.purol.2014.10.007
[10]
Tengue, K., Kpatcha, T.M., Botcho, G., Leloua, E., Amavi, A.K., Sikpa, K., et al. (2016) Epidemiological Profiles, Diagnostic, Management and Evolving Prostate Cancer in Togo. African Journal of Urology, 22, 76-82. https://doi.org/10.1016/j.afju.2015.06.006
[11]
Abdessamad, M.A. (2017) Clinic and Prognosis of Metastasis Prostate Cancer. Thèse Méd, Faculté de Médecine et de Pharmacie, Université Sidi Mohamed Ben Abdellah, N˚ 172.
[12]
Rigaud, J., Le Normand, L., Karam, G., Glemain, P., Buzelin, J.-M. and Bouchot, O. (2002) Prognosis Factors of Prostate Cancer Treated by First Line Homone Therapy. Progrès en Urologie, 12, 232-239.
[13]
Alioune, S., Yaya, S., Ibou, T., Boubacar, F., Babacar, D., Ahmed, F.P., et al. (2011) Early Detection of Prostate Cancer in Forty Years Old to Senegal. Progrès en Urologie, 21, 260-263. https://doi.org/10.1016/j.purol.2010.05.011
[14]
Carter, B.S., Bova, G.S., Beaty, T.H., Steinberg, G.D., Childs, B., Isaacs, W.B., et al. (1993) Hereditary Prostate Cancer: Epidemiologic and Clinical Features. The Journal of Urology, 150, 797-802. https://doi.org/10.1016/S0022-5347(17)35617-3
[15]
Schaid, D.J. (2004) The Complex Genetic Epidemiology of Prostate Cancer. Human Molecular Genetics, 13, 103-121. https://doi.org/10.1093/hmg/ddh072
[16]
Ndoye, M., Niang, L., Gandaho, K.I., Jalloh, M., Labou, I. and Gueye, S. (2014) Evolving Prostate Cancer in Senegal. Diagnostic Aspect in Great Yoff Hospital. Progrès en Urologie, 24, 271-275. https://doi.org/10.1016/j.purol.2013.08.317
[17]
Hounnasso, P.P., Avakoudjo, D.J.G., Traore, M., Pare, A.K., Ouattara, A., Vodounou, A., et al. (2014) Anatomy Pathologic Outcomes of Prostate Biopsy: About 127 Cases. Journal de la Société de Biologie Clinique du Bénin, 21, 93-96.
[18]
Cussenot, O., Rozet, F., Ruffion, A., Mottet, N., Bordier, B., Malavaud, B., et al. (2013) The Management of Prostate Cancer: A Retrospective Chart Review in 808 French Men Undergoing Biopsy. Progrès en Urologie, 23, 347-355. https://doi.org/10.1016/j.purol.2012.12.007
[19]
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013) Prostate Cancer: What Management in Senegal? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
[20]
Fofana, A., Kouame, B., Gowe, E.E., Kramo, N.A.F., Konan, K.P.G., Moro, A.C., et al. (2017) Metastasis Prostate Cancer: Socio-Economic Aspect, X-Ray Imaging and Evolving in Ivory Cost. African Journal of Urology, 23, 281-285. https://doi.org/10.1016/j.afju.2016.11.002
[21]
Aouagbe, H.B., Hounnasso, P.P., Avakoudjo, J.D.G. and Ouake, A. (2015) Diagnostic Aspect of Prostate Cancer in Urology Department of CNHU HKM of Cotonou. Revue Africaine d’Urologie et d’Andrologie, 1, 10-16.
[22]
Coulange, C. (2006) Good Use of PSA (Antigen Specific of Prostate): Guidelines of Urology Association of French (AFU). Memoires de l’Academie Nationale de Chirurgie, 5, 19-21.
[23]
Lopez, J.-G. and Perrin, P. (1999) Prostate Cancer: Diagnostic, Evolving, Management of Principles. La Revue du Praticien, 49, 297-301.
[24]
Salomon, L., Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., et al. (2013) Oncology-Urology Guidelines of CCAFU: Prostate Cancer. Progrès en Urologie, 23, S69-S101. https://doi.org/10.1016/S1166-7087(13)70048-4
[25]
Rozet, F., Hennequin, C., Beauval, J.-B., Beuzeboc, P., Cormier, L., Fromont-Hankard, G., et al. (2018) French Guidelines of AFU Oncology Committee-Update 2018-2020: Prostate Cancer. Progrès en Urologie, 28, S79-S130. https://doi.org/10.1016/j.purol.2018.08.011
